Skip to ContentSkip to Navigation
Over onsMedische WetenschappenResearchKindergeneeskunde
University Medical Center Groningen

CVON_GENIUS 2.0; granted 15-12-2017

15 maart 2018

Overall scientific summary

This GENIUS II proposal is built on the most promising targets identified in GENIUS I which we now aim to move towards clinical application. As such, GENIUS II builds on our unique integration of knowledge on dyslipidemia and the immune response as a consequence of dyslipidemia. The work is divided into four distinct work packages that represent the logical steps in drug development and accordingly each of the selected targets from GENIUS I to be studied was carefully placed into this track. Studies will include the actual testing of the effectiveness of small molecules, monoclonal antibodies and siRNA that modulate selected targets.The investigations will range from in vitro to in vivo analyses to improve mechanistic insight and druggability, and test effects on atherosclerosis. For five targets we already defined small molecules and a monoclonal that affect our targets. These drug leads will be further translated along toxicity studies and proof-of-pharmacology studies. We already identified three drugs affecting the current foremost targets of GENIUS I and we will study whether they can be efficiently applied to reduce atherosclerotic parameters in First-In-Human clinical studies. This will be possible through additional help of our industrial partners. In all studies, we will address gender specificity. Next to directly building on GENIUS I drug targets and drug leads, we want in this regard also take advantage of the most recent innovative developments to find new druggable targets in cells of male and female atherosclerotic lesions as well as in circulating cells (immunophenotyping and single cell sequencing.) This is also expected to lead to the identification of novel gender specific biomarkers that can facilitate identification of disease progression and improve diagnosis. Our talent program is designed in such a way that all young talent working on GENIUS II will gain insight in the opportunities and challenges of developing drugs for cardiovascular disease.

Overall, GENIUS II will focus on translating knowledge towards a clinical application.

Laatst gewijzigd:20 maart 2018 12:11

Meer nieuws

  • 21 juni 2018

    Grenzeloos lallen met Martijn Wieling op Lowlands Science

    Het is bekend dat alcoholgebruik spraak negatief beïnvloedt, maar hoe zit dat bij het spreken van een vreemde taal? Onderzoek suggereert dat het effect hier juist positief lijkt te zijn. Onduidelijk is echter wat er in de mond gebeurt. Dr. Martijn Wieling...

  • 08 juni 2018

    Waardedaling woningen in aardbevingsgebied tot 2015 gemiddeld 9,3%

    Woningen in het Groningse aardbevingsgebied zijn tot 2015 gemiddeld 9,3% in waarde gedaald. Dat concluderen promovendus Nicolás Durán en hoogleraar Ruimtelijke Econometrie Paul Elhorst van de Rijksuniversiteit Groningen. Zij analyseerden data van de...

  • 06 juni 2018

    RUG op plek 120 in QS ranking

    De Rijksuniversiteit Groningen (RUG) staat dit jaar op plaats 120 in de QS World Top University Rankings 2019. Afgelopen twee jaar stond de RUG opplaats 113 in deze lijst van bijna 1.000 universiteiten wereldwijd. Op nationale schaal is Groningen dit...